SCHEMBL13054792

SCHEMBL13054792

CN1C(=N)N[C@](C)(c2cccc(C#N)c2)[C@H](c2ccc(C3(C#N)CCC3)cc2)C1=O

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.34
BACE2 Q9Y5Z0 1/20 0.33
NSD2 O96028 1/20 0.31
ABCC9 O60706 1/20 0.31
ABCC8 Q09428 1/20 0.31
KCNJ11 Q14654 1/20 0.31
KCNJ8 Q15842 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRL1 P41146 1/20 0.31
KMT2A Q03164 1/20 0.30
DRD2 P14416 1/20 0.30
DRD3 P35462 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
ALDH1A1 P00352 2/20 0.30
PGR P06401 1/20 0.30
CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7578641 1.00 BACE1 (0.34) BACE1BACE2NSD2ABCC9ABCC8
SCHEMBL13054258 0.96 BACE1 (0.35) BACE1BACE2NSD2KMT2ASLC6A2
SCHEMBL7548240 0.96 BACE1 (0.35) BACE1BACE2NSD2KMT2ASLC6A2
SCHEMBL7580426 0.91 BACE1 (0.35) BACE1BACE2NSD2ABCC9ABCC8
SCHEMBL7590289 0.89 BACE1 (0.34) BACE1BACE2NSD2ABCC9ABCC8
SCHEMBL7542802 0.89 BACE1 (0.34) BACE1BACE2NSD2ABCC9ABCC8
SCHEMBL13055350 0.88 SLC6A2 (0.35) BACE1BACE2NSD2ABCC9ABCC8
SCHEMBL7550640 0.88 SLC6A2 (0.35) BACE1BACE2NSD2ABCC9ABCC8
SCHEMBL13054721 0.88 BACE1 (0.39) BACE1BACE2NSD2ALDH1A1PGR
SCHEMBL7574530 0.88 BACE1 (0.39) BACE1BACE2NSD2ALDH1A1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed
WO-2008103351-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 BACE1 8/4885BACE2 30/4885NSD2 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.